Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

Future GB logo


FUTURE-GB, an NIHR EME funded study, has opened with Southmead Hospital in Bristol as the first recruiting site.  Glioblastoma (GB) is the most common primary brain tumour and is incurable -with a poor prognosis for most patients. FUTURE-GB is a 2-stage trial, looking at the use of additional imaging technologies before and during adult glioblastoma surgery to improve patient outcomes and quality of life. Stage 1 of the trial is an IDEAL IIB study, with each patient receiving the additional imaging to ensure standardisation of practice with the technologies at each recruiting site. Stage 2 is the full randomised controlled trial, recruiting 357 participants from 15 neurosurgical centres across the UK. The whole trial will recruit for 33 months, and patient quality of life will be assessed for up to 2 years.